Zhang Jing, Zheng Jianming, Yang Yinghong, Lu Junliang, Gao Jie, Lu Tao, Sun Jian, Jiang Hui, Zhu Yan, Zheng Yuhui, Liang Zhiyong, Liu Tonghua
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, People's Republic of China.
Department of Pathology, Changhai Hospital of Shanghai, Shanghai, People's Republic of China.
Sci Rep. 2015 Dec 22;5:18678. doi: 10.1038/srep18678.
Mutations in genes such as KRAS, NRAS, BRAF and PIK3CA have become an important part of colorectal carcinoma evaluation. The aim of this study was to screen for mutations in these genes in Chinese patients with colorectal cancer (CRC) and to explore their correlations with certain clinicopathological parameters. We tested mutations in the KRAS (exons 2, 3 and 4), NRAS (exons 2, 3 and 4), PIK3CA (exon 20) and BRAF (exon 15) genes using reverse transcriptase-polymerase chain reaction (RT-PCR) and Sanger sequencing in a large cohort of 1,110 Chinese CRC patients who underwent surgical resection at one of three major teaching hospitals located in different regions of China. The prevalence rates of KRAS, NRAS, BRAF and PIK3CA mutations were 45.4%, 3.9%, 3.1% and 3.5%, respectively. Mutant KRAS was associated with the mucinous subtype and greater differentiation, while mutant BRAF was associated with right-sided tumors and poorer differentiation. Our results revealed differences in the genetic profiles of KRAS, NRAS, PIK3CA and BRAF at mutation hotspots between Chinese CRC patients and those of Western countries, while some of these gene features were shared among patients from other Asian countries.
KRAS、NRAS、BRAF和PIK3CA等基因的突变已成为结直肠癌评估的重要组成部分。本研究旨在筛查中国结直肠癌(CRC)患者这些基因的突变情况,并探讨其与某些临床病理参数的相关性。我们在中国不同地区的三家主要教学医院之一接受手术切除的1110例中国CRC患者的大样本队列中,使用逆转录聚合酶链反应(RT-PCR)和桑格测序法检测了KRAS(第2、3和4外显子)、NRAS(第2、3和4外显子)、PIK3CA(第20外显子)和BRAF(第15外显子)基因的突变。KRAS、NRAS、BRAF和PIK3CA突变的发生率分别为45.4%、3.9%、3.1%和3.5%。KRAS突变与黏液亚型和更高分化相关,而BRAF突变与右侧肿瘤和更低分化相关。我们的结果显示,中国CRC患者与西方国家患者在KRAS、NRAS、PIK3CA和BRAF突变热点的基因谱存在差异,而其中一些基因特征在其他亚洲国家的患者中是共有的。